Drug Profile


Latest Information Update: 08 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northeastern University; University of Bonn
  • Developer Northeastern University; NovoBiotic Pharmaceuticals; University of Bonn
  • Class Anti-infectives; Depsipeptides; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Tuberculosis; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 30 Jun 2016 Chemical structure information added
  • 28 Jan 2015 NovoBiotic receives SBIR grant from the the National Institute of Allergy and Infectious Diseases for preclinical development of teixobactin in Gram-positive infections (NovoBiotic Pharmaceuticals website)
  • 22 Jan 2015 Preclinical trials in Gram-positive infections in USA (IV) before January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top